About Us

Revance Therapeutics, Inc. is a privately held biopharmaceutical company developing products that will change the way that drugs are delivered.

The com­pany's pro­prie­tary Trans­MTS™ techno­logy has de­mon­strated the abil­ity to carry act­ive levels of drug across the skin to de­liv­er at spe­cif­ic and tar­geted depths - en­abling top­ic­al de­liv­ery of macromolecules and elim­in­at­ing needles.

Our lead in­vest­ig­a­tion­al product util­iz­ing the Trans­MTS tech­no­logy is a phys­i­cian-ap­plied top­ic­al botulin­um tox­in type A (BoNTA) pro­duct being developed for cos­met­ic and the­ra­peut­ic in­dica­tions (RT001). Eliminating needles from treatment with BoNTA could significantly expand the market by removing many of the barriers to entry.

Revance has the exclusive rights to a portfolio of highly purified BoNTA proteins for use across all dose forms for all indications worldwide.

Our proprietary BoNTA proteins and TransMTS technology have applications beyond the initial dermatology focus: our pipeline includes research programs in other therapeutic areas, and we are pursuing licensing opportunities for use of TransMTS with additional compounds.